EC Number   |
Protein Variants |
Reference |
|---|
   3.2.1.166 | D367A |
mutant enzyme is not expressed |
690874 |
| 3.2.1.166 | E144A |
site-directed mutagenesis, conserved active site residue mutant |
754818 |
| 3.2.1.166 | E255A |
site-directed mutagenesis, conserved active site residue mutant |
754818 |
| 3.2.1.166 | more |
a splice variant of the Spalax enzyme lacking 16 aa encoded by exon 7. This deletion results in a major defect in trafficking and processing of the heparanase protein, leading to a loss of its enzymatic activity |
694846 |
| 3.2.1.166 | more |
deletion mutants lacking heparin binding domains (Lys158-Asn162 or Gln270-Lys280) exhibit no enzymatic activity |
692975 |
| 3.2.1.166 | more |
enzyme silencing by different siRNAs, overview |
732954 |
| 3.2.1.166 | more |
generation of heparanase-knockout (Hpa-KO) mice, reduced cytokine expression and motility of heparanase-deficient macrophages, phenotype, overview |
755259 |
| 3.2.1.166 | more |
generation of Hpa-tg mice in which transgenic heparanase is driven by a constitutive beta-actin promoter in a BALB/c genetic background. The skin of Hpa-tg mice has normal appearance and is characterized by an enhanced hair re-growth, no differences in proliferation of interfollicular keratinocytes between healthy Hpa-tg and wild-type mice. Heparanase overexpression preserves psoriasislike phenotype in mouse skin following multiple 12-O-tetradecanoyl phorbol 12-myristate 13-acetate application |
-, 731626 |
| 3.2.1.166 | more |
reduced enzyme expression in enzyme-silenced cells |
731355 |
| 3.2.1.166 | Q225A |
mutation results in the complete loss of heparanase activity |
690874 |
